Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug
For the first time in 12 years, the FDA has approved a new frontline treatment for the most common form of liver cancer.
The agency …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
